PT - JOURNAL ARTICLE AU - Thomas Nedelec AU - Baptiste Couvy-Duchesne AU - Fleur Monnet AU - Timothy Daly AU - Manon Ansart AU - Laurène Gantzer AU - Béranger Lekens AU - Stéphane Epelbaum AU - Carole Dufouil AU - Stanley Durrleman TI - Data-driven identification of health conditions associated with incident Alzheimer’s disease dementia risk: a 15 years follow-up cohort from electronic health records in France and the United Kingdom AID - 10.1101/2021.06.07.21258454 DP - 2021 Jan 01 TA - medRxiv PG - 2021.06.07.21258454 4099 - http://medrxiv.org/content/early/2021/06/13/2021.06.07.21258454.short 4100 - http://medrxiv.org/content/early/2021/06/13/2021.06.07.21258454.full AB - Importance The identification of modifiable risk factors for Alzheimer’s disease (AD) is paramount for early prevention and the targeting of new interventions.Objective To assess the associations between health conditions diagnosed in primary care and the risk of incident AD over time.Design, Setting, and Participants Data for 20,214 AD patients from the United Kingdom and 19,458 AD patients from France were extracted from The Health Improvement Network (THIN) database. For each AD case, a control was randomly assigned after matching for sex and age at dementia diagnosis. We agnostically tested the associations between 123 different ICD10 diagnoses extracted from health records and AD dementia, by conditional logistic regression. We focused on two time periods: 2 to 10 years vs. 0 to 2 years before the diagnosis of AD, to separate risk factors from early symptoms/comorbidities.Exposures We considered all health conditions that had been recorded in more than 0.1% of visits per 1000 person-years in both cohorts, corresponding to 123 potential types of exposure.Main Outcomes and Measures Odds ratios (ORs) for the association of AD with the various health conditions were calculated after Bonferroni correction for multiple comparisons.Results Ten health conditions were significantly associated with high odds ratios for AD when diagnosed 2 to 10 years before AD, in the British and French samples: major depressive disorder (OR 95% confidence interval (UK):1.23-1.46)), anxiety (1.25-1.47), reaction to severe stress (1.24-1.59), hearing loss (1.11-1.28), constipation (1.22-1.41), spondylosis (1.14-1.39), abnormal weight loss (1.33-1.63), malaise and fatigue (1.14-1.32), memory loss (6.65-8.76) and syncope and collapse (1.1-1.37). Depression was the first comorbid condition associated with AD, appearing at least nine years before the first clinical diagnosis of AD, followed by, anxiety, constipation and abnormal weight loss.Conclusions and Relevance These results from two independent primary care databases provide new evidence on the temporality of risk factors and early signs of Alzheimer’s disease. These results could guide new dementia prevention strategies.Competing Interest StatementSE reports personal fees from Biogen, Eisai, Roche, and GE Healthcare, for presentations or participation to advisory boards. FM, LG and BE are full time employees of Cegedim. Other authors declare no competing interests.Funding StatementThis work was funded in part by the Agence Nationale de la Recherche, as part of the "Investissements d'avenir" program, under grants ANR-10-IAIHU-06 (IHU-ICM) and ANR-19-P3IA-0001 (PRAIRIE 3IA Institute). BCD is supported by a CJ Martin Fellowship (NHMRC, APP1161356).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The French database obtained approval for data collection from the French National Data Protection Authority (CNIL) in 2002. For the UK database, ethical approval was granted by the NHS South-East Multicentre Research Ethics Committee in 2003 (ref: 03/01/073) for establishment of the THIN database, and it was updated in 2011. The study was a retrospective analysis of secondary anonymised patient data only.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in the preparation of the article are available from the Cegedim company upon reasonable request.